Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate against the Novel Influenza A (H1N1) Virus.
Novavax, Inc. (NASDAQ NVAX) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) have signed an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced influenza A (H1N1) VLP vaccine against the strain recommended by the Centers for Disease Control and Prevention (CDC).
Be sure to take a look at this FREE analysis information below. Just put in NVAX, your first name & e-mail address and a realtime analysis will come right to your in-box. NVAX scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend)
Strong Uptrend
NOVAVAX INC (NASDAQ:NVAX)
Smart Scan Chart Analysis confirms that a strong uptrend and a triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
FREE Trend analysis for NVAX Here
